Veritas In Silico Inc
130A
Company Profile
Business description
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
Contact
1-11-1, Nishigotanda
Shinagawa-ku
Tokyo141-0031
JPNT: +81 -364217537
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
Is this the catalyst US tech giant needs?
Muse models may just be the spark that the rirm needed in AI model development.
stocks
ASX share plunges due to Iran related weakness
Despite headwinds our long-term outlook is unchanged.
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,113.40 | 6.40 | 0.07% |
| CAC 40 | 8,190.65 | 68.95 | -0.83% |
| DAX 40 | 23,552.12 | 251.83 | -1.06% |
| Dow JONES (US) | 47,916.57 | 269.23 | -0.56% |
| FTSE 100 | 10,555.81 | 44.72 | -0.42% |
| HKSE | 25,660.85 | 232.69 | -0.90% |
| NASDAQ | 22,902.89 | 80.48 | 0.35% |
| Nikkei 225 | 56,502.77 | 421.34 | -0.74% |
| NZX 50 Index | 13,020.18 | 161.26 | -1.22% |
| S&P 500 | 6,816.89 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,926.00 | 14.20 | 0.16% |
| SSE Composite Index | 3,988.56 | 2.33 | 0.06% |